Medpace Holdings, Inc., incorporated in Delaware on February 18, 2014, is one of the world's leading clinical contract research organizations (CROs) focused on providing science-oriented outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company provides full-process clinical development services covering stages I to IV, and has outstanding advantages in therapeutic areas such as oncology, metabolic diseases, cardiology, antiviral and anti-infective (AVAI) and central nervous system (CNS). Medpace operates in all major therapeutic areas and, with its standardized operating model, is committed to providing timely, high-quality and cost-effective clinical trial services to small and medium-sized biopharmaceutical companies, making it a priority partner.
